Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
Hong Kong · Delayed Price · Currency is HKD 3.960
-0.030 (-0.75%)
At close: Mar 27, 2026
HKG:2185 Revenue
In the year 2025, Shanghai Bio-heart Biological Technology had annual revenue of 44.93M CNY. Shanghai Bio-heart Biological Technology had revenue of 20.86M in the half year ending June 30, 2025.
Revenue
44.93M CNY
Revenue Growth
n/a
P/S Ratio
19.28
Revenue / Employee
641.89K CNY
Employees
70
Market Cap
963.93M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.93M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 589.59M |
| 3D Medicines | 491.34M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Brii Biosciences | 39.56M |
| Kintor Pharmaceutical | 12.04M |